OGEN — Oragenics Inc
NYSE MKT · Healthcare · Biotechnology
$0.50
+$0.00 (+0.04%)
Oragenics Inc (OGEN) is a biotechnology company listed on NYSE MKT. It is led by Janet Huffman, based in 1990 Main Street, Sarasota, FL, United States, 34236, with about 3 employees. Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.
Net income was -$3.1M. OGEN currently screens at market cap $2.7M.
Use this OGEN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OGEN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OGEN SEC filings page. Lician reads the product cache first so this HTML stays unique to Oragenics Inc even when a live quote feed is slow.
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.
OGEN Key Statistics
Market Cap
$2.73M
Volume
12,883
Previous Close
$0.52
Day Range
$0.51 – $0.53
EPS
-$1.60
Revenue
$0.00
Net Income
-$10.57M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
3
OGEN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $37.65K | $131.52K | $86.99K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$10.57M | -$20.66M | -$14.29M | -$15.71M |
| EPS (Diluted) | -$1.60 | -$9.18 | -$7.11 | $0.00 |
Total Assets
$1.47M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$864.84K
Operating Cash Flow
-$8.60M
Free Cash Flow
$0.00
Oragenics Inc Company Information
- CEO, President, CFO, Secretary & Treasurer
- Janet Huffman
- Headquarters
- 1990 Main Street, Sarasota, FL, United States, 34236
- Website
- www.oragenics.com
- Phone
- 813 286 7900
- IPO / Founded
- 2004-02-25
- Sector
- Healthcare
- Industry
- Biotechnology